- $1.93bn
- $676.81m
- $548.51m
Brief: Hutchmed (China) Reports FY Net Income $ 37.7 Million
2024 Final Results and Business Updates
Brief: Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint
Vesting of awards under Long Term Incentive Plan
Advisory: Incorrect revenue alert on Hutchmed (China) withdrawn
Notice of Extraordinary General Meeting
Completed Enrollment of Phase II Study
Directorate Change
Notice of Results
Brief: Hutchmed (China) Says Disposal Of Stake In Shanghai Hutchison Pharmaceuticals
Brief: HUTCHMED (China) Says NMPA Granted Full Approval For Orpathys (Savolitinib) In China
Full Approval for ORPATHYS in China
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
China NDA Acceptance for ORPATHYS and TAGRISSO
Overseas Regulatory Announcement
US$608m Divestment of Non-Core Joint Venture
HK-listed Hutchmed jumps on health unit stake sales
Brief: Hutchmed (China) Announces NDA Acceptance With Priority Review Status For Orpathys And Tagrisso